Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Falk

Showing results (391-400 of 421) with videos related to

Pageof 43
Sort By:
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 20, 2025
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trialStephanie S O'Malley, Robert Miranda, Sarah W Book, et al.
Alcoholism, Clinical and Experimental Research|September 29, 2011
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsRaye Z Litten, Joanne B Fertig, Daniel E Falk, et al.
Journal of Addiction Medicine|June 4, 2013
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependenceRaye Z Litten, Megan L Ryan, Joanne B Fertig, et al.
Alcoholism, Clinical and Experimental Research|February 14, 2012
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patientsJoanne B Fertig, Megan L Ryan, Daniel E Falk, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 24, 2016
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol DependenceMegan L Ryan, Daniel E Falk, Joanne B Fertig, et al.
American Journal of Medical Genetics|January 8, 1999
Mosaic trisomy 16 ascertained through amniocentesis: evaluation of 11 new casesW T Hsu, D A Shchepin, R Mao, et al.
Drug and Alcohol Dependence|December 15, 2015
Measures of outcome for stimulant trials: ACTTION recommendations and research agendaBrian D Kiluk, Kathleen M Carroll, Amy Duhig, et al.
Journal of Medical Genetics|February 25, 2016
Clinical course of sly syndrome (mucopolysaccharidosis type VII)Adriana M Montaño, Ngu Lock-Hock, Robert D Steiner, et al.
Alcoholism, Clinical and Experimental Research|November 8, 2018
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and SafetyDaniel E Falk, Megan L Ryan, Joanne B Fertig, et al.
Nature Reviews. Gastroenterology & Hepatology|June 7, 2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus StatementBrian P Lee, Katie Witkiewitz, Jessica Mellinger, et al.
Pageof 43

Showing results (391-400 of 421) with videos related to

Sort By:
Pageof 43
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 20, 2025
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trialStephanie S O'Malley, Robert Miranda, Sarah W Book, et al.
Alcoholism, Clinical and Experimental Research|September 29, 2011
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsRaye Z Litten, Joanne B Fertig, Daniel E Falk, et al.
Journal of Addiction Medicine|June 4, 2013
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependenceRaye Z Litten, Megan L Ryan, Joanne B Fertig, et al.
Alcoholism, Clinical and Experimental Research|February 14, 2012
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patientsJoanne B Fertig, Megan L Ryan, Daniel E Falk, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 24, 2016
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol DependenceMegan L Ryan, Daniel E Falk, Joanne B Fertig, et al.
American Journal of Medical Genetics|January 8, 1999
Mosaic trisomy 16 ascertained through amniocentesis: evaluation of 11 new casesW T Hsu, D A Shchepin, R Mao, et al.
Drug and Alcohol Dependence|December 15, 2015
Measures of outcome for stimulant trials: ACTTION recommendations and research agendaBrian D Kiluk, Kathleen M Carroll, Amy Duhig, et al.
Journal of Medical Genetics|February 25, 2016
Clinical course of sly syndrome (mucopolysaccharidosis type VII)Adriana M Montaño, Ngu Lock-Hock, Robert D Steiner, et al.
Alcoholism, Clinical and Experimental Research|November 8, 2018
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and SafetyDaniel E Falk, Megan L Ryan, Joanne B Fertig, et al.
Nature Reviews. Gastroenterology & Hepatology|June 7, 2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus StatementBrian P Lee, Katie Witkiewitz, Jessica Mellinger, et al.
Pageof 43